Mn Services Vermogensbeheer B.V. Raises Position in Pfizer Inc. $PFE

Mn Services Vermogensbeheer B.V. grew its stake in Pfizer Inc. (NYSE:PFE) by 1.8% in the 3rd quarter, Holdings Channel.com reports. The firm owned 2,159,000 shares of the biopharmaceutical company’s stock after purchasing an additional 38,800 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Pfizer were worth $55,011,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Curio Wealth LLC boosted its stake in Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,098 shares during the period. Harbor Asset Planning Inc. bought a new stake in shares of Pfizer in the 2nd quarter worth about $29,000. Grey Fox Wealth Advisors LLC purchased a new position in shares of Pfizer during the 3rd quarter worth about $29,000. Howard Hughes Medical Institute bought a new position in Pfizer during the 2nd quarter valued at about $30,000. Finally, Darwin Wealth Management LLC purchased a new stake in Pfizer in the 2nd quarter worth about $32,000. Institutional investors own 68.36% of the company’s stock.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: NICE recommended Pfizer’s PARP inhibitor Talzenna for adults with prostate cancer — a UK endorsement that supports incremental oncology revenue and validates Pfizer’s targeted‑therapy strategy. NICE backs Pfizer’s Talzenna for adults with prostate cancer
• Positive Sentiment: Pfizer launched a large Phase 3 lung‑cancer trial positioning its regimen against Merck’s Keytruda — a successful outcome would target a high‑value oncology market and materially boost long‑term growth expectations. Pfizer Takes Aim at Keytruda in New Phase 3 Lung Cancer Study: What Investors Should Know
• Positive Sentiment: Pfizer moved a COPD candidate into a Phase 2/3 trial, strengthening its post‑COVID respiratory pipeline and the company’s addressable market in chronic lung disease. Pfizer Advances New COPD Candidate Into Phase 2/3, Adding Depth to Its Post-COVID Pipeline
• Positive Sentiment: Novavax and Pfizer reached a licensing agreement on the Matrix‑M adjuvant — this could reshape Pfizer’s vaccine platform strategy by expanding adjuvant options and serviceable vaccine markets. Novavax inks license agreement with Pfizer
• Positive Sentiment: Early‑stage pipeline progress: PF‑07248144 advanced with a drug–interaction study and PF‑08065010 entered Phase 1 — steady, low‑visibility pipeline work that reduces binary risk over time. Pfizer Advances PF-07248144 With New Drug–Interaction Study, Signaling Quiet Pipeline Progress
• Neutral Sentiment: Large options flow: traders bought ~446,836 call options (≈+114% vs. typical volume) — indicates short‑term bullish/speculative positioning but not a direct fundamental signal. (Market data)
• Neutral Sentiment: CEO Albert Bourla publicly criticized RFK Jr.’s vaccine views and warned the U.S. risks falling behind China in health research — a strong management stance on science and policy that can influence regulatory/public perception but is not an immediate earnings driver. Pfizer CEO Calls RFK’s Vaccine Views Anti-Science, Warns US Falling Behind China In Health Research
• Negative Sentiment: Investor concerns persist on pricing and post‑COVID revenue sustainability — recent pieces question whether Pfizer’s current valuation reflects secular headwinds and pricing pressure, which helps explain selling pressure despite pipeline news. Is Pfizer (PFE) Pricing Make Sense After Post Covid Slowdown Concerns
• Negative Sentiment: Opinion pieces highlight a debate whether Pfizer is an attractive dividend/value play or a value trap — ongoing skepticism around growth prospects can keep the stock depressed. Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap?

Pfizer Price Performance

Shares of PFE stock opened at $25.65 on Friday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The stock has a fifty day simple moving average of $25.40 and a two-hundred day simple moving average of $25.01. The stock has a market capitalization of $145.82 billion, a price-to-earnings ratio of 14.91 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. Pfizer’s payout ratio is currently 100.00%.

Analysts Set New Price Targets

Several brokerages have issued reports on PFE. Morgan Stanley dropped their target price on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. UBS Group started coverage on Pfizer in a research note on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 target price on the stock. HSBC reiterated a “buy” rating and set a $29.00 target price on shares of Pfizer in a research report on Wednesday, December 10th. Finally, BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a report on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus price target of $27.88.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.